Our analysis demonstrated that cg13892570 and cg16107628 significantly reduced PAH risk by downregulating TAGLN2 expression, with TAGLN2 mediating the majority of the effect (86.46% and 97.65%, respectively). Here, TAGLN2 is linked to pulmonary arterial hypertension.